Can CMV reactivation be a biomarker of persistent inflammation, immunosuppression, and catabolism syndrome?
Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) is a multifactorial condition characterized by prolonged inflammation, immune dysfunction, and muscle wasting that occurs in some critically ill patients after they have recovered from their acute illness [1] [2]. Cytomegalov...
Gespeichert in:
Veröffentlicht in: | Journal of critical care 2024-06, Vol.81, p.154742, Article 154742 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 154742 |
container_title | Journal of critical care |
container_volume | 81 |
creator | Dogan, Lerzan Zengin, Rehile Kocagöz, Sesin Akinci, Ibrahim Ozkan |
description | Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) is a multifactorial condition characterized by prolonged inflammation, immune dysfunction, and muscle wasting that occurs in some critically ill patients after they have recovered from their acute illness [1] [2]. Cytomegalovirus (CMV) reactivation is a common viral infection observed in critically ill patients and has been associated with immune dysregulation [3] [4]. This study aims to investigate the incidence of CMV reactivation in critical patients who have developed PICS.
This is a data-based, observational, and cohort study. All patients with CMV reactivation admitted to the ICU between January 01, 2018, and May 01, 2023, were reviewed and those with PICS were analyzed. CMV reactivation was defined as CMV DNA ≥1000 copies/ml in tracheal samples. PICS was assessed using established clinical criteria, including inflammation and muscle wasting markers, at regular intervals during the ICU stay. The patient population was analyzed in two groups: CMV-reactivated PICS patients and CMV-non-reactivated PICS patients.
During the study period, CMV reactivation was detected in 85.5% of all PICS patients. The results showed that the CMV-positive group had significantly higher APACHE-II scores at ICU admission and a higher prevalence of diabetes mellitus and cancer. According to the multivariate logistic regression model for CMV reactivation, APACHE-II score, steroid use, and the presence of thrombocytopenia were identified as significant variables. Additionally, the CMV-positive group was found to have a higher mortality rate.
The incidence of CMV reactivation is very high in patients with PICS, and this condition appears to be associated with worse outcomes. Comorbidities such as steroid use, cancer, and diabetes mellitus are considered risk factors. Our findings suggest that CMV testing should be considered in patients suspected of having PICS. Understanding the relationship between CMV reactivation and PICS could pave the way for potential biomarker-based diagnostic and therapeutic approaches, enabling early identification and intervention for individuals at risk. Further prospective studies are needed to elucidate CMV reactivation's precise mechanisms and clinical implications in these complex syndromes. |
doi_str_mv | 10.1016/j.jcrc.2024.154742 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3020341736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0883944124002296</els_id><sourcerecordid>3020341736</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1246-f04218bdc0df134fbfdc05e32402cb69de340c35823cefb5bdf7a0376b9e2f4c3</originalsourceid><addsrcrecordid>eNp9kFtLAzEQhYMoWKt_wKeAr-6a214KgsjiDSq-qK8hyU4g226yJttC_73b1mefZhjOmZnzIXRNSU4JLe-6vDPR5IwwkdNCVIKdoBktiiqrS1qcohmpa54thKDn6CKljhBacV7M0KpRHjfv3ziCMqPbqtEFjzVghbULvYoriDhYPEBMLo3gR-y8Xau-Pyhvsev7jQ9pMwwRUjqMlG-xUaPSYe1Sj9POtzH08HCJzqxaJ7j6q3P09fz02bxmy4-Xt-ZxmRnKRJlZIhitdWtIaykXVtupLYAzQZjR5aIFLojhRc24AasL3dpKEV6VegHMCsPn6Oa4d4jhZwNplF3YRD-dlJwwwsWUvZxU7KgyMaQUwcohuinwTlIi91BlJ_dQ5R6qPEKdTPdHE0z_bx1EmYwDb6B1Ecwo2-D-s_8Cp_eBxg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3020341736</pqid></control><display><type>article</type><title>Can CMV reactivation be a biomarker of persistent inflammation, immunosuppression, and catabolism syndrome?</title><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Dogan, Lerzan ; Zengin, Rehile ; Kocagöz, Sesin ; Akinci, Ibrahim Ozkan</creator><creatorcontrib>Dogan, Lerzan ; Zengin, Rehile ; Kocagöz, Sesin ; Akinci, Ibrahim Ozkan</creatorcontrib><description>Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) is a multifactorial condition characterized by prolonged inflammation, immune dysfunction, and muscle wasting that occurs in some critically ill patients after they have recovered from their acute illness [1] [2]. Cytomegalovirus (CMV) reactivation is a common viral infection observed in critically ill patients and has been associated with immune dysregulation [3] [4]. This study aims to investigate the incidence of CMV reactivation in critical patients who have developed PICS.
This is a data-based, observational, and cohort study. All patients with CMV reactivation admitted to the ICU between January 01, 2018, and May 01, 2023, were reviewed and those with PICS were analyzed. CMV reactivation was defined as CMV DNA ≥1000 copies/ml in tracheal samples. PICS was assessed using established clinical criteria, including inflammation and muscle wasting markers, at regular intervals during the ICU stay. The patient population was analyzed in two groups: CMV-reactivated PICS patients and CMV-non-reactivated PICS patients.
During the study period, CMV reactivation was detected in 85.5% of all PICS patients. The results showed that the CMV-positive group had significantly higher APACHE-II scores at ICU admission and a higher prevalence of diabetes mellitus and cancer. According to the multivariate logistic regression model for CMV reactivation, APACHE-II score, steroid use, and the presence of thrombocytopenia were identified as significant variables. Additionally, the CMV-positive group was found to have a higher mortality rate.
The incidence of CMV reactivation is very high in patients with PICS, and this condition appears to be associated with worse outcomes. Comorbidities such as steroid use, cancer, and diabetes mellitus are considered risk factors. Our findings suggest that CMV testing should be considered in patients suspected of having PICS. Understanding the relationship between CMV reactivation and PICS could pave the way for potential biomarker-based diagnostic and therapeutic approaches, enabling early identification and intervention for individuals at risk. Further prospective studies are needed to elucidate CMV reactivation's precise mechanisms and clinical implications in these complex syndromes.</description><identifier>ISSN: 0883-9441</identifier><identifier>EISSN: 1557-8615</identifier><identifier>DOI: 10.1016/j.jcrc.2024.154742</identifier><language>eng</language><publisher>Philadelphia: Elsevier Inc</publisher><subject>Biomarker ; Biomarkers ; Catabolism syndrome ; CMV reactivation ; Critical care ; Cytomegalovirus ; Diabetes ; Immunosuppression ; Inflammation ; Persistent inflammation ; Steroids</subject><ispartof>Journal of critical care, 2024-06, Vol.81, p.154742, Article 154742</ispartof><rights>2024</rights><rights>Copyright Elsevier Limited Jun 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3020341736?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982,64370,64374,72224</link.rule.ids></links><search><creatorcontrib>Dogan, Lerzan</creatorcontrib><creatorcontrib>Zengin, Rehile</creatorcontrib><creatorcontrib>Kocagöz, Sesin</creatorcontrib><creatorcontrib>Akinci, Ibrahim Ozkan</creatorcontrib><title>Can CMV reactivation be a biomarker of persistent inflammation, immunosuppression, and catabolism syndrome?</title><title>Journal of critical care</title><description>Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) is a multifactorial condition characterized by prolonged inflammation, immune dysfunction, and muscle wasting that occurs in some critically ill patients after they have recovered from their acute illness [1] [2]. Cytomegalovirus (CMV) reactivation is a common viral infection observed in critically ill patients and has been associated with immune dysregulation [3] [4]. This study aims to investigate the incidence of CMV reactivation in critical patients who have developed PICS.
This is a data-based, observational, and cohort study. All patients with CMV reactivation admitted to the ICU between January 01, 2018, and May 01, 2023, were reviewed and those with PICS were analyzed. CMV reactivation was defined as CMV DNA ≥1000 copies/ml in tracheal samples. PICS was assessed using established clinical criteria, including inflammation and muscle wasting markers, at regular intervals during the ICU stay. The patient population was analyzed in two groups: CMV-reactivated PICS patients and CMV-non-reactivated PICS patients.
During the study period, CMV reactivation was detected in 85.5% of all PICS patients. The results showed that the CMV-positive group had significantly higher APACHE-II scores at ICU admission and a higher prevalence of diabetes mellitus and cancer. According to the multivariate logistic regression model for CMV reactivation, APACHE-II score, steroid use, and the presence of thrombocytopenia were identified as significant variables. Additionally, the CMV-positive group was found to have a higher mortality rate.
The incidence of CMV reactivation is very high in patients with PICS, and this condition appears to be associated with worse outcomes. Comorbidities such as steroid use, cancer, and diabetes mellitus are considered risk factors. Our findings suggest that CMV testing should be considered in patients suspected of having PICS. Understanding the relationship between CMV reactivation and PICS could pave the way for potential biomarker-based diagnostic and therapeutic approaches, enabling early identification and intervention for individuals at risk. Further prospective studies are needed to elucidate CMV reactivation's precise mechanisms and clinical implications in these complex syndromes.</description><subject>Biomarker</subject><subject>Biomarkers</subject><subject>Catabolism syndrome</subject><subject>CMV reactivation</subject><subject>Critical care</subject><subject>Cytomegalovirus</subject><subject>Diabetes</subject><subject>Immunosuppression</subject><subject>Inflammation</subject><subject>Persistent inflammation</subject><subject>Steroids</subject><issn>0883-9441</issn><issn>1557-8615</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kFtLAzEQhYMoWKt_wKeAr-6a214KgsjiDSq-qK8hyU4g226yJttC_73b1mefZhjOmZnzIXRNSU4JLe-6vDPR5IwwkdNCVIKdoBktiiqrS1qcohmpa54thKDn6CKljhBacV7M0KpRHjfv3ziCMqPbqtEFjzVghbULvYoriDhYPEBMLo3gR-y8Xau-Pyhvsev7jQ9pMwwRUjqMlG-xUaPSYe1Sj9POtzH08HCJzqxaJ7j6q3P09fz02bxmy4-Xt-ZxmRnKRJlZIhitdWtIaykXVtupLYAzQZjR5aIFLojhRc24AasL3dpKEV6VegHMCsPn6Oa4d4jhZwNplF3YRD-dlJwwwsWUvZxU7KgyMaQUwcohuinwTlIi91BlJ_dQ5R6qPEKdTPdHE0z_bx1EmYwDb6B1Ecwo2-D-s_8Cp_eBxg</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Dogan, Lerzan</creator><creator>Zengin, Rehile</creator><creator>Kocagöz, Sesin</creator><creator>Akinci, Ibrahim Ozkan</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>202406</creationdate><title>Can CMV reactivation be a biomarker of persistent inflammation, immunosuppression, and catabolism syndrome?</title><author>Dogan, Lerzan ; Zengin, Rehile ; Kocagöz, Sesin ; Akinci, Ibrahim Ozkan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1246-f04218bdc0df134fbfdc05e32402cb69de340c35823cefb5bdf7a0376b9e2f4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biomarker</topic><topic>Biomarkers</topic><topic>Catabolism syndrome</topic><topic>CMV reactivation</topic><topic>Critical care</topic><topic>Cytomegalovirus</topic><topic>Diabetes</topic><topic>Immunosuppression</topic><topic>Inflammation</topic><topic>Persistent inflammation</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dogan, Lerzan</creatorcontrib><creatorcontrib>Zengin, Rehile</creatorcontrib><creatorcontrib>Kocagöz, Sesin</creatorcontrib><creatorcontrib>Akinci, Ibrahim Ozkan</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of critical care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dogan, Lerzan</au><au>Zengin, Rehile</au><au>Kocagöz, Sesin</au><au>Akinci, Ibrahim Ozkan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can CMV reactivation be a biomarker of persistent inflammation, immunosuppression, and catabolism syndrome?</atitle><jtitle>Journal of critical care</jtitle><date>2024-06</date><risdate>2024</risdate><volume>81</volume><spage>154742</spage><pages>154742-</pages><artnum>154742</artnum><issn>0883-9441</issn><eissn>1557-8615</eissn><abstract>Persistent Inflammation, Immunosuppression, and Catabolism Syndrome (PICS) is a multifactorial condition characterized by prolonged inflammation, immune dysfunction, and muscle wasting that occurs in some critically ill patients after they have recovered from their acute illness [1] [2]. Cytomegalovirus (CMV) reactivation is a common viral infection observed in critically ill patients and has been associated with immune dysregulation [3] [4]. This study aims to investigate the incidence of CMV reactivation in critical patients who have developed PICS.
This is a data-based, observational, and cohort study. All patients with CMV reactivation admitted to the ICU between January 01, 2018, and May 01, 2023, were reviewed and those with PICS were analyzed. CMV reactivation was defined as CMV DNA ≥1000 copies/ml in tracheal samples. PICS was assessed using established clinical criteria, including inflammation and muscle wasting markers, at regular intervals during the ICU stay. The patient population was analyzed in two groups: CMV-reactivated PICS patients and CMV-non-reactivated PICS patients.
During the study period, CMV reactivation was detected in 85.5% of all PICS patients. The results showed that the CMV-positive group had significantly higher APACHE-II scores at ICU admission and a higher prevalence of diabetes mellitus and cancer. According to the multivariate logistic regression model for CMV reactivation, APACHE-II score, steroid use, and the presence of thrombocytopenia were identified as significant variables. Additionally, the CMV-positive group was found to have a higher mortality rate.
The incidence of CMV reactivation is very high in patients with PICS, and this condition appears to be associated with worse outcomes. Comorbidities such as steroid use, cancer, and diabetes mellitus are considered risk factors. Our findings suggest that CMV testing should be considered in patients suspected of having PICS. Understanding the relationship between CMV reactivation and PICS could pave the way for potential biomarker-based diagnostic and therapeutic approaches, enabling early identification and intervention for individuals at risk. Further prospective studies are needed to elucidate CMV reactivation's precise mechanisms and clinical implications in these complex syndromes.</abstract><cop>Philadelphia</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jcrc.2024.154742</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0883-9441 |
ispartof | Journal of critical care, 2024-06, Vol.81, p.154742, Article 154742 |
issn | 0883-9441 1557-8615 |
language | eng |
recordid | cdi_proquest_journals_3020341736 |
source | ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
subjects | Biomarker Biomarkers Catabolism syndrome CMV reactivation Critical care Cytomegalovirus Diabetes Immunosuppression Inflammation Persistent inflammation Steroids |
title | Can CMV reactivation be a biomarker of persistent inflammation, immunosuppression, and catabolism syndrome? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T13%3A12%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20CMV%20reactivation%20be%20a%20biomarker%20of%20persistent%20inflammation,%20immunosuppression,%20and%20catabolism%20syndrome?&rft.jtitle=Journal%20of%20critical%20care&rft.au=Dogan,%20Lerzan&rft.date=2024-06&rft.volume=81&rft.spage=154742&rft.pages=154742-&rft.artnum=154742&rft.issn=0883-9441&rft.eissn=1557-8615&rft_id=info:doi/10.1016/j.jcrc.2024.154742&rft_dat=%3Cproquest_cross%3E3020341736%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3020341736&rft_id=info:pmid/&rft_els_id=S0883944124002296&rfr_iscdi=true |